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To evaluate the performance of dried blood spots (DBSs) with subsequent analyses of glutamic acid decarboxylase (GADA) and
islet antigen-2 (IA-2A) with the RSR-ELISAs, we selected 80 children newly diagnosed with type 1 diabetes and 120 healthy
women. DBSs from patients and controls were used for RSR-ELISAs while patients samples were analysed also with in-house
RIAs. The RSR-ELISA-GADA performed well with a speciﬁcity of 100%, albeit sensitivity (46%) was lower compared to in RIA
(56%; P = .008). No prozone eﬀect was observed after dilution of discrepant samples. RSR-ELISA-IA-2A achieved speciﬁcity of
69% and sensitivity was lower (59%) compared with RIA (66%; P<. 001). Negative or low positive patients and control samples
in the RSR-ELISA-IA-2A increased after dilution. Eluates from DBS can readily be used to analyse GADA with the RSR-ELISA,
even if low levels of autoantibodies were not detected. Some factor could disturb RSR-ELISA-IA-2A analyses.
1.Introduction
Sampling of blood as dried blood spots (DBSs) for clinical
use is currently used for such diverse diseases as congenital
metabolic disorders, diabetes, and HIV infections [1–4].
There are a number of advantages gained when using the
DBS-technique with subsequent elution concerning ease of
collection, transportation/storage, small blood volumes, and
minimal invasiveness compared with serum samples. DBS-
technique facilitates sampling procedures since capillary
sampling can be used. The capillary blood sampling requires
less skill and fewer supplies, it can even be used by diabetes
patients at home if they are used to measuring their own
blood glucose levels. DBS samples can easily be mailed
since there is no risk of leakage. Both transportation and
short time storage can be done at room temperature [5, 6].
In many countries, all newborn babies are screened for
phenylketonuria, galactosemia, congenital hypothyroidism,
and other metabolic disorders using dried blood spots,
indicating that this technique is suitable for large scale
analyses [7–9]. The DBS-samples can be used for both
genetic factors (DNA) [10] and proteins (enzymes and
antibodies) [5, 11].
Five islet autoantibodies are known to characterize
type 1 diabetes, namely, islet cell antibodies (ICA), insulin
autoantibodies (IAA), glutamic acid decarboxylase anti-
bodies (GADA), islet antigen-2 antibodies (IA-2A), and
antibodies against the beta cell speciﬁc zink-transporter
(ZnT8A) [12]. The ﬁrst four of these are well characterized
and several workshops have been undertaken to standardize
the measurement of these autoantibodies in serum [13–15].
Both in-house RIAs and RSR-ELISA kits are well established2 Experimental Diabetes Research
for analyses of GADA as well as for IA-2A. The RSR-ELISA
kits show high performance for both GADA and IA-2A
in serum samples [15]a n dC a 2+-treated plasma can also
be used [16, 17]. In DASP 2005, both RSR-ELISA-GADA
kits and RSR-ELISA-IA-2A kits achieved high sensitivity
and speciﬁcity [15]. For RSR-ELISA-GADA kits (n = 7)
sensitivity varied from 84% to 94% and speciﬁcity from
97% to 99% for serum samples. For RSR-IA-2A-ELISA kits,
sensitivityrangedfrom64%to68%andspeciﬁcityfrom98%
to 100% for serum samples. In DASP 2005, our in-house
RIA-GADAassaygaveasensitivityof76%andaspeciﬁcityof
91% for serum samples, and our in-house RIA-IA-2A assay
gave a sensitivity of 72% and a speciﬁcity of 100%. GADA
and IA-2A have been analysed in whole blood eluates with
RIA assays with high performance [18, 19].
In this study, we wanted to test if GADA and IA-2A can
be analysed from whole blood eluates with RSR-ELISAs. If
these assays show high performances, the measurements of
GADA and IA-2A using ELISA have a potential to be applied
inlargescreeningprogramsforidentifyingindividualsatrisk
for type 1diabetes.
2.MaterialsandMethods
2.1. Subjects. Dried blood spots (DBS) were obtained as
EDTA-blood spotted onto ﬁlter forms (Parajett, Parajett
AB, Landskrona, Sweden, with ﬁlters from Schleicher and
Schuell, Dassel, Germany) and air-dried before transporta-
tion to the laboratory. A minimum of 60μL blood was
needed to ﬁll the marked circles on the ﬁlters.
The study population consisted of a random selection
of children with newly diagnosed type 1 diabetes (n = 80;
median age 10yrs; range 2–18; M/F = 1.29) and healthy
control women were obtained from ﬁve Maternity Clinics
in our region as described [20]( n = 120; median age
32yrs; range 19–44). The patient’s (DBSs) had been stored at
roomtemperatureforamedianof56days(range8–150)and
(DBSs)fromcontrolshadbeenstoredforamedianof18days
(range 5–57) before punching with subsequent elution was
performed.
All samples were collected under informed consent, as
approved by the Ethical Committee at Lund University,
Lund.
2.2. Sample Preparation. Discs with a diameter of 6mm
were punched out with a special punching device (Wallac
Delﬁa dried blood spots puncher prod no. 1296-071, Wallac,
Turku, Finland). Four discs were punched out from each
specimen into separate wells. A total of 80μLo fT B S T - b u ﬀer
(150mmol/L NaCl, 20mmol/L Tris, pH7.4, 0.15% Tween20,
0.1% BSA) was added to each well. Samples were left on
a plateshaker (Delﬁa plateshaker 1296-003, Wallac, Turku,
Finland) at 500rpm, at +4◦C overnight. Next morning,
whole blood eluates were spun down (1min, 1500×g,
Labofuge400,Heraeus,Langerbold,Germany).Wholeblood
eluates were pooled into an Eppendorf-micro tube and spun
at 10000×g for 10min to remove cell debris.
2.3. Assays
2.3.1. RSR-ELISA Assays. RSR-ELISA kits for GADA
(GDE/96) and IA-2A (IAE/96) (RSR Ltd, Pentwyn, Cardiﬀ,
UK) were used for analyses of GADA and IA-2A. The assays
were performed according to the instructions from the
manufacturer, except that whole blood eluates were used
in equal amounts as recommended for serum. Optical
density was read on an ELISA platereader (E-max, Multical
platereader, Molecular Devices Corporation, Menlo Park,
CA, USA) at 450nm, with software Multicalc (Perkin-Elmer,
Waltham, MA, USA).
Standards were calibrated against the WHO reference
NIBSC (97/550) for the GADA assay [21]. High values
(>250 WHO Units/ml) were replaced with 250 for statistical
and clinical evaluations. The cut-oﬀ level was set to 5
WHO Units/ml for GADA, which is the lowest standard
concentration and also the recommended cut-oﬀ by the
manufacturer for serum samples.
Also for IA-2A, standards were calibrated against the
NIBSC (97/550). High values (>400 WHO Units/ml) were
replaced with 400 for statistical and clinical evaluations.
The cut-oﬀ level was set to 15 WHO Units/ml for IA-
2A, which is the lowest standard concentration and also
the recommended cut-oﬀ by the manufacturer for serum
samples. Duplicate sampling including the whole preanalytic
procedure was performed in ten subjects for GADA and
IA-2A. The coeﬃcient of variation (CV) was calculated as
the ratio between standard deviation and mean value for
duplicates. The median value of these observations was 6.3%
(range 0.76–13) for GADA in the range of 5.0–46.4 WHO
Units/ml. Interassay variation for the same samples in two
repetitions was a median 7.7% (range 1.8%–40%). The CV
for IA-2A was a median 5.0% (range 0.77–15) in the range
15–25WHOUnits/ml.Interassayvariationintworepetitions
was a median 46% (range 25%–88%).
Samples with a high level of antibodies (GADA or IA-
2A) in the in-house RIA, but low in the ELISA were diluted
to reveal if this ﬁnding could be validated or was due to the
prozone eﬀect. The prozone eﬀect is well-known to interfere
with titers for ICA [22, 23].
2.3.2. In-House RIA for GADA and IA-2A. Aliquots of 30μL
of whole blood eluates were obtained using the procedure
described in Sample preparation and were added into wells
with30μLo f35S-radiolabelled antigen (GAD65 or IA-2) and
incubated overnight on a plateshaker (500rpm) at +4◦C.
Next morning, plates were spun for 1min 1500×g. Dupli-
cates of 50μL of the antibody-antigen-complex-solution
were added to 50μL of 20% rProtein A Sepharose Fast Flow
(Amersham Biosciences, Uppsala, Sweden) and incubated
for 90minutes at +4◦C on a plateshaker (500rpm). Excess
antigen was removed by repeated washing of plates (8
times with cold TBST-buﬀer) using a special washing device
(Multiscreenvacuumwasher,Millipore,Bedford,MA,USA).
Plates were air-dried for 30min, before addition of 50μLo f
scintillation liquid (Optiphase Supermix scintillation ﬂuid,
PerkinElmer Life Sciences, Boston, MA, USA) to each well.Experimental Diabetes Research 3
The radioactivity was measured in a beta counter (Microbeta
counter, PerkinElmer Life Sciences, Boston, MA, USA).
Logaritmic standard curves were used for the GADA
assay and IA-2A assay. Our laboratory uses the WHO-
standardaslocalstandard.Samplesabove50WHO-Units/ml
were considered as positive in the GADA assay as were
samples above 10 WHO-Units/ml in the IA-2A assay. These
cut-oﬀ limits were deﬁned using previous results from
healthy individuals. A GADA level of 500 WHO Units/ml
and an IA-2A level of 250 WHO Units/ml were considered
as endpoints for samples analysed with RIA and were not
diluted further.
ThemedianCVforduplicateswas3.5%(range0–15;n =
29) for GADA and interassay variation was 10.1% (n = 29)
for a sample of 35 WHO Units/ml. For another sample of 96
WHO Units/ml, median CV was 3.1 % (range 0–11; n = 29)
and interassay variation was 8.7% (n = 29).
ThemedianCVforduplicateswas3.7%(range0–10:n =
30) for IA-2A and interassay variation was 7.8% (n = 30)
for a sample of 24 WHO Units/ml. For another sample of
155 WHO Units/ml the median CV was 2.7% (range 0–11:
n = 24) and interassay variation was 9.7%.
2.3.3. Statistical Analysis. Results are reported as median,
interquartile range and minimum and maximum since not
normally distributed. If P-values were <. 05 a signiﬁcant
diﬀerence was accepted. Wilcoxons signed rank test was used
to test for diﬀerences in repeated measurements in continuos
variables.
McNemars test was used to test for diﬀerences in binom-
inal paired observations (positive and negative results).
3. Results
3.1. RSR-ELISA-GADA Assay Characteristics for Measure-
mentsfromWholeBloodEluates. Thethresholdof5.0WHO-
Units/ml corresponded to a speciﬁcity of 100% and a
sensitivity of 46% (37/80; Table 1). A total of 8 samples
showed a concentration of 250 WHO Units/ml or higher,
these samples were diluted and showed ﬁnal concentrations
of 222-2460 WHO-Units/ml.
3.2. Comparisons of RSR-ELISA-GADA and an In-House RIA
Using Patient’s Samples. The RSR-ELISA-GADA achieved
lower sensitivity 46% (37/80) compared with the in-house
RIA 56% (45/80; P = .008; Figure 1). All samples (n = 37)
that were positive in the RSR-ELISA-GADA were also posi-
tive in the in-house RIA. The discordant samples were alllow
level positive samples in the in-house RIA (n = 8; range 53–
125 WHO-Units/ml; threshold 50 WHO-Units/ml). Twelve
samples were high when analysed with the in-house RIA
(range 198–≥ 500 WHO-Units/ml) but relatively low in the
RSR-ELISA (range 7.3–46 WHO-Units/ml). These samples
were checked for prozone eﬀect by dilution but levels were
similar after dilution (range 10–52; P = .81). There was a
correlation in GADA levels in patient’s samples found to be
positive in both assays (n = 37; rs = 0.82; P<. 01; Figure 2).
Moreover, GADA levels analysed in double-positive samples
Table 1: Estimation of positivity for GADA and IA-2A. Number
of positive and negative patients (80 children newly diagnosed with
type 1 diabetes; median age 10; range 2–18yrs) and controls (120
healthy women; median 32; range 19–44yrs) from Sweden.
Assay Positive Negative
Patients (n = 80)
RSR-ELISA-GADA 37 (46%) 43 (54%)
In-house RIA-GADA 45 (56%) 35 (44%)
Controls (n = 120)
RSR-ELISA-GADA 0 (0%) 120 (100%)
In-house RIA-GADA NA NA
Patients (n = 80)
RSR-ELISA-IA-2A 47 (59%) 33 (41%)
In-house RIA-IA-2A 53 (66%) 27 (34%)
Controls (n = 120)
RSR-ELISA-IA-2A 37 (31%) 83 (69%)
In-house RIA-IA-2A NA NA
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Figure 1: GADA levels detected by both ELISA and RIA assays. Cut
oﬀ levels are indicated by dashed lines.
were higher in the in-house RIA (n = 37; median ≥ 500
WHO Units/ml; interquartile range 235–≥ 500) compared
to GADA levels analysed with ELISA (n = 37; median 32
WHO Units/ml; interquartile range 11–189; P<. 001).
3.3.RSR-ELISA-IA-2AAssayCharacteristicsforMeasurements
from Whole Blood Eluates. Using the cut-oﬀ of 15 WHO-
Units/ml the speciﬁcity was 69% (83/120) and the sensitivity
was 59% (47/80; Table 1). A total of 16 samples were
400 WHO Units/ml or higher, after dilution the ﬁnal
concentrations of those samples were ranging from 365 to
3430 WHO-Units/ml.
3.4. Comparisons of RSR-ELISA-IA-2A and an In-House RIA
Using Patient’s Samples. The RSR-ELISA-IA-2A achieved
lower sensitivity 59% (47/80) compared with the in-house
RIA 66% (53/80; P<. 001; Figure 3). Five low level positive
samples in the RSR-ELISA-IA-2A (17–35 WHO Units/ml)
were negative in the in-house RIA. Eleven samples were
positive only in the in-house RIA (range 17–≥ 250), six of4 Experimental Diabetes Research
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Figure 2: GADA levels correlated in patient’s samples positive in
both the RSR-ELISA and an in-house RIA (n = 37; rs = 0.82;
P<. 01).
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Figure 3: IA-2A levels detected by both ELISA and RIA assays. Cut
oﬀ levels are indicated by dashed lines.
these samples were 214 WHO Units/ml or higher. We re-
analysed two discordant samples that were high level positive
in the RIA but negative in the ELISA (with sample material
left) and another four samples that were high in the IA-2A
RIA (n = 6; range 193–≥ 250 WHO-Units/ml) but low
in the RSR-ELISA (n = 6; range 11–36 WHO-Units/ml).
After dilution IA-2A levels increased in all samples (n = 6;
range 113–516 WHO-Units/ml; P = .028) when analysed in
the RSR-ELISA-IA-2A. Four patient’s samples that were all
negative in the in-house RIA, three of whom were low level
positive in the RSR-ELISA and one that was negative (n = 4;
range 11–35 WHO-Units/ml) were diluted and reanalysed in
the RSR-ELISA and also in this case, levels increased (n =
4; range 82–888 WHO-Units/ml). Furthermore, 10 control
samples found to be clearly negative in the RSR-ELISA
(n = 10; range 8–13 WHO-Units/ml) were also diluted
and reanalysed and also in this case levels were higher when
diluted (range 29–127 WHO-Units/ml; P = .005). A total
of 42samples were positive in both assays. There was a weak
correlation between IA-2A double positive samples analysed
with ELISA and RIA (n = 42; rs = 0.52; P<. 01; Figure 4).
Nevertheless, for IA-2A double positive samples, levels were
similar in the in-house RIA (n = 42; median ≥ 250 WHO
Units/ml; interquartile range ≥ 250 –≥ 250) compared with
ELISA (median 162 WHO Units/ml; interquartile range 44–
≥ 400; P = .76).
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Figure 4: A weak correlation was found in IA-2A levels in positive
samples both in the RSR-ELISA and an in-house RIA (n = 42; rs =
0.52; P<. 01).
3.5. Combined Sensitivity for GADA and IA-2A with In-House
RIA and RSR-ELISAAs. Combining the results from GADA
and IA-2A measurements with in-house RIAs increased the
sensitivity for detecting type 1 diabetes to 79% (63/80; P =
.0020). Likewise, combining the results from GADA and IA-
2A measurements with RSR-ELISAs increased the sensitivity
to71%(57/80;P = .0020)andexpectedspeciﬁcitydecreased
to 69% (83/120).
4. Discussion
In this study, we compared in-house RIAs with commercial
ELISAs for analyses of GADA and IA-2A from whole blood
eluates both qualitatively and quantitatively. We found that
speciﬁcity was excellent (100%) for the RSR-ELISA-GADA,
while sensitivity was lower (46%) compared with the in-
house RIA (56%). Discordant samples that were negative in
theRSR-ELISA-GADAwerelowlevelpositiveinthein-house
RIA. Moreover, GADA levels were lower in the RSR-ELISA
in samples found to be positive in both assays. Samples
found to have high GADA levels in the in-house RIA, but
low in the RSR-ELISA were reanalysed in dilution but levels
did not increase. These ﬁndings indicate that samples that
are positive in the RSR-ELISA-GADA are concordant with
measurements in the in-house RIA. However, the RSR-
ELISA failed to detect low level GADA. The lower frequency
and lower levels of GADA positive samples can be due to
interference of haemoglobin or some other factor in the
whole blood. The possibility to measure very high level
autoantibodies has little importance in the routine clinical
laboratory but can be of interest in intervention studies
aimed to decrease levels of autoantibodies [24].
ThespeciﬁcitywasverylowforRSR-ELISA-IA-2A(69%)
and also the sensitivity was lower for the RSR-ELISA-IA-
2A (59%) compared with the in-house RIA (66%). Among
the discordant patient samples, most were high level positive
in the in-house RIA. When two of the discordant samples
and also four other patient’s samples found to be low level
positiveornegativeintheRSR-ELISA-IA-2Awerereanalysed
in dilution in the RSR-ELISA, levels increased signiﬁcantly.
Also when ten control samples were reanalysed in dilution,Experimental Diabetes Research 5
IA-2A levels increased. We believe that haemoglobin or some
other factor in whole blood interfered with the measurement
of the antibodies, either via a direct binding to the antigen
or antibodies or through a colour shift that aﬀected the
optical density, even though we have not fully examined
the impact of haemoglobin in this study. It must be borne
in mind that these commercial kits are recommended for
analyses of autoantibodies in serum. One limitation with our
study is that we have not analysed paired serum and DBS
samples from patients and controls. However, a similar set
of patient serum samples have shown excellent performance
for the RSR-ELISA-GADA and IA-2A in our hands [17].
Both our in-house RIAs for GADA and IA-2A achieved
high sensitivities (76% and 72%) at excellent speciﬁcities in
DASP 2005 [15]. RSR-ELISAs for GADA and IA-2A were
recentlyestablishedattheDepartmentofClinicalChemistry,
UMAS, Malm¨ o and have not been subjected to international
standardisation. Another possible limitation with our study
is that our reference population consisted of only women.
Nonetheless, GADA has been shown to be more frequently
found in women with type 1 diabetes than in men and
also levels are higher in women [25, 26]. Samples were
drawn prior to delivery in these women used as the control
population. Pregnancy could decrease immune response,
but GADA has been detected at higher frequency among
women with gestational diabetes compared with the general
population [27]. Therefore, we assume that we have not
limited the ability to detect GADA positive subjects in this
reference population using the cut-oﬀ limits recommended
by the manufacturer.
We have not done a speciﬁc study on reproducibility
over time due to limited amount of specimens. However,
GADA and IA-2A autoantibodies are of IgG type [28]
as are HIV-antibodies [29]. HIV-antibodies have shown
e x c e l l e n tr e p r o d u c i b i l i t yf o ru pt os i xw e e k si nd i ﬀerent
storage conditions (room temperature,4◦C, −20
◦C, −70
◦C,
and also 37–70
◦C) [6]. Total IgE has been also shown
to be stable for repeated freeze/thaw cycles [5]. HbA1c,
another protein frequently used for analyses with DBS-
technique, has shown low (less than 2%) between-day
imprecision for both venous and capillary sampling [1].
Furthermore, our ﬁndings indicate that strong haemolysis
may interfere with analyses of IA-2A using the RSR-ELISA.
It is possible that haemoglobin caused the lower sensitivity
fortheRSR-ELISA-GADAbutspeciﬁcitywasexcellentinthis
case.
In conclusion, the RSR-ELISA can be used for measure-
ment of GADA in whole blood eluates in a reliable manner
even if sensitivity is lower compared with an in-house RIA.
Some factor could disturb RSR-ELISA-IA-2A analyses.
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